Active	Status	Sponsor type	Region	Phase	Filter
6 Active 0 Inactive 6 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes: « July » « 2025 » M T W T F S S 30 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 1 2 3   - « July » « 2025 » M T W T F S S 30 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 1 2 3   Show only changed items Enrollment:

Advanced Filters

6 Trials

Active Trials   

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Turek-Urasinska, Katarzyna
NCT06239311: Efficacy and Safety of Methotrexate Versus Placebo in Adults With Atopic Dermatitis.	Recruiting	3	212	Europe, RoW	Methotrexate, Placebo	medac GmbH	Moderate to Severe Atopic Dermatitis	11/25	03/26
BRAVE-AA-PEDS, NCT05723198: A Study of Baricitinib (LY3009104) in Children From 6 Years to Less Than 18 Years of Age With Alopecia Areata	Recruiting	3	595	Europe, Canada, Japan, US, RoW	Baricitinib, LY3009104, Placebo	Eli Lilly and Company	Areata Alopecia, Alopecia, Hypotrichosis, Hair Diseases, Skin Diseases, Pathological Conditions, Anatomical	09/27	08/29
AtDvance, NCT06447506: Long-Term Study () to Evaluate GSK1070806 in Atopic Dermatitis.	Active, not recruiting	2	79	Europe, Canada, Japan, US, RoW	GSK1070806	GlaxoSmithKline	Dermatitis, Atopic	07/25	07/25
RECAST DLE, NCT05591222 / 2022-000831-21: Study of Daxdilimab (HZN-7734) in Participants With Moderate-to-Severe Primary Discoid Lupus Erythematosus	Terminated	2	72	Europe, Canada, US, RoW	Placebo, Daxdilimab, HZN-7734	Amgen, Horizon Therapeutics Ireland DAC	Discoid Lupus Erythematosus	05/25	05/25
NCT06602219: A Study of LY4100511 (DC-853) in Adult Participants With Moderate-to-Severe Plaque Psoriasis	Recruiting	2	220	Europe, Canada, Japan, US, RoW	LY4100511, Placebo	DICE Therapeutics, Inc., a wholly owned subsidiary of Eli Lilly and Company	Plaque Psoriasis	07/25	08/25
NCT05999799: A Dose Finding Study to Investigate the Safety and Effectiveness of GSK1070806 in Adult Participants With Moderate to Severe Atopic Dermatitis	Active, not recruiting	2	163	Europe, Canada, Japan, US, RoW	GSK1070806, Placebo	GlaxoSmithKline	Dermatitis, Atopic	07/25	07/25

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Turek-Urasinska, Katarzyna
NCT06239311: Efficacy and Safety of Methotrexate Versus Placebo in Adults With Atopic Dermatitis.	Recruiting	3	212	Europe, RoW	Methotrexate, Placebo	medac GmbH	Moderate to Severe Atopic Dermatitis	11/25	03/26
BRAVE-AA-PEDS, NCT05723198: A Study of Baricitinib (LY3009104) in Children From 6 Years to Less Than 18 Years of Age With Alopecia Areata	Recruiting	3	595	Europe, Canada, Japan, US, RoW	Baricitinib, LY3009104, Placebo	Eli Lilly and Company	Areata Alopecia, Alopecia, Hypotrichosis, Hair Diseases, Skin Diseases, Pathological Conditions, Anatomical	09/27	08/29
AtDvance, NCT06447506: Long-Term Study () to Evaluate GSK1070806 in Atopic Dermatitis.	Active, not recruiting	2	79	Europe, Canada, Japan, US, RoW	GSK1070806	GlaxoSmithKline	Dermatitis, Atopic	07/25	07/25
RECAST DLE, NCT05591222 / 2022-000831-21: Study of Daxdilimab (HZN-7734) in Participants With Moderate-to-Severe Primary Discoid Lupus Erythematosus	Terminated	2	72	Europe, Canada, US, RoW	Placebo, Daxdilimab, HZN-7734	Amgen, Horizon Therapeutics Ireland DAC	Discoid Lupus Erythematosus	05/25	05/25
NCT06602219: A Study of LY4100511 (DC-853) in Adult Participants With Moderate-to-Severe Plaque Psoriasis	Recruiting	2	220	Europe, Canada, Japan, US, RoW	LY4100511, Placebo	DICE Therapeutics, Inc., a wholly owned subsidiary of Eli Lilly and Company	Plaque Psoriasis	07/25	08/25
NCT05999799: A Dose Finding Study to Investigate the Safety and Effectiveness of GSK1070806 in Adult Participants With Moderate to Severe Atopic Dermatitis	Active, not recruiting	2	163	Europe, Canada, Japan, US, RoW	GSK1070806, Placebo	GlaxoSmithKline	Dermatitis, Atopic	07/25	07/25